10x Genomics

TXG

Market cap $2.38B

Initiative led by researchers in Australia and Japan aims to map cancer and immune interactions to advance precision oncology across the region PLEASANTON, Calif. and SYDNEY , Nov. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc.

PLEASANTON, Calif. , Nov. 11, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Wolfe Research Healthcare Conference 2025 on Tuesday, November 18, at 11:20 a.m.

10x Genomics, Inc. ( TXG ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Cassie Corneau - Manager of Investor Relations & Strategic Finance Serge Saxonov - Co-Founder, CEO & Director Adam Taich - CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Madeline Mollman Puneet Souda - Leerink Partners LLC, Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division David Westenberg - Piper Sandler & Co., Research Division Kyle Boucher - TD Cowen, Research Division Lu Li - UBS Investment Bank, Research Division Michael Ryskin - BofA Securities, Research Division Justin Bowers - Deutsche Bank AG, Research Division Jaden Rismay - JPMorgan Chase & Co, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Benjamin Mee - Stephens Inc., Research Division Presentation Operator Thank you for standing by. Welcome to the 10X Genomics' Third Quarter 2025 Earnings Conference Call.

While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

10x Genomics (TXG) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.3 per share a year ago.

PLEASANTON, Calif. , Nov. 6, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2025.

Torex Gold Resources Inc. ( TXG:CA ) Q3 2025 Earnings Call November 6, 2025 9:00 AM EST Company Participants Dan Rollins - Senior Vice President of Corporate Development & Investor Relations Jody Kuzenko - CEO, President & Non-Independent Director Andrew Snowden - Chief Financial Officer Conference Call Participants Cosmos Chiu - CIBC Capital Markets, Research Division Don DeMarco - National Bank Financial, Inc., Research Division Allison Carson - Desjardins Securities Inc., Research Division Lauren McConnell - Paradigm Capital Inc., Research Division Presentation Operator Thank you for standing by. This is the conference operator.

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New plate-based multiplexing unlocks ultra high-sample and cell-throughput single cell analysis to empower a broad range of studies PLEASANTON, Calif. , Oct. 29, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of the next generation of its high-performance Flex assay, featuring automation-compatible plate-based multiplexing.

Lancaster Investment Management bought over 620,000 shares in 10x Genomics (TXG) worth around $7.27 million. 10x Genomics, a new holding for the investment manager, now accounts for 3.1% of its AUM.